Published in PLoS One on November 06, 2013
Dynamic instability of microtubule growth. Nature (1984) 20.32
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Microtubule polymerization dynamics. Annu Rev Cell Dev Biol (1997) 12.39
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem (1997) 5.51
Aurora B-mediated abscission checkpoint protects against tetraploidization. Cell (2009) 5.26
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A (1993) 5.11
Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell (2004) 4.90
Molecular mechanisms of drug resistance. J Pathol (2005) 4.60
Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci (1992) 4.00
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Chemotherapy-induced peripheral neuropathy. J Neurol (2002) 3.09
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res (2001) 2.62
How do anti-mitotic drugs kill cancer cells? J Cell Sci (2009) 2.38
NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization. J Cell Biol (2003) 2.13
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther (2009) 2.10
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol (2007) 1.90
Multiple drug resistance mechanisms in cancer. Mol Biotechnol (2010) 1.84
Epothilones: mechanism of action and biologic activity. J Clin Oncol (2004) 1.80
Cohesion fatigue induces chromatid separation in cells delayed at metaphase. Curr Biol (2011) 1.60
Modulated microtubule dynamics enable Hklp2/Kif15 to assemble bipolar spindles. Cell Cycle (2011) 1.58
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol (2008) 1.53
Uncoordinated loss of chromatid cohesion is a common outcome of extended metaphase arrest. PLoS One (2011) 1.45
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest (1995) 1.30
Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol (2009) 1.18
Automatic quantification of microtubule dynamics enables RNAi-screening of new mitotic spindle regulators. Cytoskeleton (Hoboken) (2011) 1.15
Eribulin mesylate. Nat Rev Drug Discov (2011) 1.14
The halichondrins and E7389. Chem Rev (2009) 1.07
The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J (2006) 1.02
Eribulin mesylate. Clin Cancer Res (2011) 0.93
Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat (2011) 0.87
Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene (2000) 0.86
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol (2009) 0.82
Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett (2008) 0.80
Analysis of microtubule assembly kinetics using turbidimetry. Methods Mol Biol (2011) 0.79
The Mad1/Mad2 complex as a template for Mad2 activation in the spindle assembly checkpoint. Curr Biol (2005) 3.77
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med (2005) 2.89
Systematic kinetic analysis of mitotic dis- and reassembly of the nuclear pore in living cells. J Cell Biol (2008) 2.30
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23
Notch signaling induces multilineage myeloid differentiation and up-regulates PU.1 expression. J Immunol (2003) 1.29
Pattern recognition by Toll-like receptors. Adv Exp Med Biol (2009) 1.27
TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol (2008) 1.20
Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9. Immunobiology (2007) 1.19
Sun1 forms immobile macromolecular assemblies at the nuclear envelope. Biochim Biophys Acta (2008) 1.12
Fluorophores for live cell imaging of AGT fusion proteins across the visible spectrum. Biotechniques (2006) 1.08
Drosophila Pez acts in Hippo signaling to restrict intestinal stem cell proliferation. Curr Biol (2012) 1.06
TLR9-mediated recognition of DNA. Handb Exp Pharmacol (2008) 0.95
Notch signaling in embryonic and adult myelopoiesis. Cells Tissues Organs (2008) 0.94
Novel components of an active mitochondrial K(+)/H(+) exchange. J Biol Chem (2010) 0.92
Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs. Oligonucleotides (2007) 0.90
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol (2009) 0.88
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.88
A major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC? Proc Natl Acad Sci U S A (2010) 0.85
Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement. Bioorg Med Chem Lett (2004) 0.85
An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant. Eur J Pharm Sci (2012) 0.85
Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK. Antiviral Res (2013) 0.84
N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping. Bioorg Med Chem Lett (2009) 0.83
Proteasome inhibition by peptide-semicarbazones. Bioorg Med Chem (2008) 0.83
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett (2009) 0.82
A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype. Acta Neuropathol (2014) 0.82
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients. J Proteomics (2012) 0.80
Thienopyrimidines as β3-adrenoceptor agonists: hit-to-lead optimization. Bioorg Med Chem Lett (2010) 0.80
A combined proteomic and genetic analysis of the highly variable platelet proteome: from plasmatic proteins and SNPs. J Proteomics (2012) 0.79
SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors. Bioorg Med Chem Lett (2005) 0.79
Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors. Bioorg Med Chem Lett (2005) 0.76
Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1δ and ε with nanomolar inhibitory activity on cancer cell proliferation. J Med Chem (2014) 0.76
Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun (2017) 0.75
Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization. Bioorg Med Chem (2009) 0.75
The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells. Br J Haematol (2009) 0.75
A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett (2010) 0.75
Discovery and hit-to-lead optimization of novel allosteric glucokinase activators. Bioorg Med Chem Lett (2011) 0.75